17-AAG (Tanespimycin)

17-AAG (Tanespimycin)は、5nMのIC50による強力な熱ショックタンパク質90(Hsp90)阻害剤です。

目録号S1141
5 5 3レビュー 9製品表彰状
価格 在庫  
USD 189 In stock
USD 245 In stock
USD 466 In stock
USD 718 In stock

17-AAG (Tanespimycin) 化学構造
分子量: 585.69

品質と確認

カスタマーレビュー(3)

Quality Control & MSDS

製品情報

製品の説明

生物活性

情報 17-AAG (Tanespimycin)は、5nMのIC50による強力な熱ショックタンパク質90(Hsp90)阻害剤です。
目標 HSP90
IC50 5 nM [1]
In vitro試験 17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]
In vivo試験 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]
臨床試験 A Phase II study of 17-AAG in patients with relapsed/refractory CD30 plus anaplastic large cell lymphoma (ALCL) relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory classical Hodgkin's lymphoma (HL) has been completed.
特集 Displays very low toxicity toward normal cells.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Hsp90 binding assays Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.

細胞アッセイ: [1]

細胞系 BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
濃度 Dissolved in DMSO, final concentrations ~10 μM
処理時間 5 days
方法 Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.

動物実験: [2]

動物モデル Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
製剤 Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
投薬量 ~50 mg/kg
管理 Injection i.p.
1

参考

化学情報

Download 17-AAG (Tanespimycin) SDF
分子量 585.69
化学式

C31H43N3O8

CAS No. 75747-14-7
別名 CP127374
溶解度 (25°C)
  • DMSO 117 mg/mL
  • 水 <1 mg/mL
  • エタノール 5 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 Geldanamycin, 17-demethoxy-17-(2-propenylamino)-

研究分野

カスタマーレビュー (3)


Click to enlarge
Rating
Source THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287(53), pp. 44109–44120. 17-AAG (Tanespimycin) purchased from Selleck
Method Western Blot
Cell Lines Dopaminergic Neuronal Cell lines
Concentrations 10-20uM
Incubation Time
Results As expected, both complex IV activity and Hsp60 levels exhibited a dose-dependent decrease in response to treatment with 17-AAG (Fig. 4A). However, 17-AAG treatment did not alter levels of Hsp90 and LRPPRC levels

Click to enlarge
Rating
Source AGE, 2012. 17-AAG (Tanespimycin) purchased from Selleck
Method Western Blot
Cell Lines HFSN1 cells
Concentrations 0.1/0.5uM
Incubation Time 24 h
Results Figure 2c shows that the decrease in the level of Hsp90 after treatment with 0.5 μM of 17-AAG was accompanied by a decrease in the level of both the survivin and phospho-survivin proteins.

Click to enlarge
Rating
Source PNAS, 2011, 108, 7535-40. 17-AAG (Tanespimycin) purchased from Selleck
Method Western blot
Cell Lines H3122 CR cells
Concentrations 10 nM
Incubation Time 72 h
Results As shown in Fig. A, 17-AAG potently suppressed cell growth in both parental H3122 and H3122 CR cells.However, in contrast to NVP-TAE684 and AP26113, 17-AAG also inhibited the viability of SKBR3 and BT474 cell lines, both of which harbor HER2 amplification and are known to be sensitive to Hsp90 inhibition (26, 27). 17-AAG treatment decreased both p-ALK level and ALK protein expression with similar potencies in the parental and resistant cells (Fig. B).

製品表彰状 (9)

  • Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. [Weigert O, et al. J Exp Med 2012;209(2):259-73]

    PubMed: 22271575
  • Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. [Katayama R, et al. Proc Natl Acad Sci U S A 2011;108(18):7535-40]

    PubMed: 21502504
  • SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis. [Častorálová M, et al. Biochim Biophys Acta 2012;1823(4):911-9]

    PubMed: 22306003
  • Rescue of PINK1 Protein Null-specific Mitochondrial Complex IV Deficits by Ginsenoside Re Activation of Nitric Oxide Signaling. [Kim KH, et al. J Biol Chem 2012;287(53):44109-20]

    PubMed: 23144451
  • Survivin expression increases during aging and enhances the resistance of aged human fibroblasts to genotoxic stress. [Al-Khalaf HH, et al. Age (Dordr) 2012;35(3):549-62]

    PubMed: 22252435
  • Joint inhibition of TOR and JNK pathways interacts to extend the lifespan of Brachionus manjavacas (Rotifera). [Snell TW, et al. Exp Gerontol 2014;10.1016/j.exger.2014.01.022]

    PubMed: 24486130
  • The hormone-dependent function of Hsp90 in the crosstalk between 20-hydroxyecdysone and juvenile hormone signaling pathways in insects is determined by differential phosphorylation and protein interactions. [Liu W, et al. Biochim Biophys Acta 2013;1830(11):5184-92]

    PubMed: 23850472
  • Heat-shock protein 90 (Hsp90) is Required for Conidiation and Cell Wall Integrity in Aspergillus fumigatus. [Lamoth F, et al. Eukaryot Cell 2012;11(11):1324-32]

    PubMed: 22822234
  • Chaxamycins A-D, bioactive ansamycins from a hyper-arid desert Streptomyces sp. [Rateb ME, et al. J Nat Prod 2011;74(6):1491-9]

    PubMed: 21553813

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related HSP (e.g. HSP90) 阻害剤

  • Elesclomol (STA-4783)

    Elesclomol (STA-4783)は、新しい強力な酸化性ストレス誘導物です。

  • AUY922 (NVP-AUY922)

    AUY922 (NVP-AUY922)は高度的に HSP90 を抑制、 HSP90α と HSP90β を作用すると、 IC50 がそれぞれ 13 nM 、 21 nM となる。

  • 17-DMAG (Alvespimycin) HCl

    17-DMAG (Alvespimycin) HClは、62nMのIC50による強力なHsp90阻害剤です。

  • Ganetespib (STA-9090)

    Ganetespib (STA-9090)は独特な triazolone-containing Hsp90阻害剤、 IC50 が4 nM となる.

  • AT13387

    AT13387は、A375細胞の18nMのIC50による選択的な強力な熱ショックタンパク質90(Hsp90)阻害剤です。

  • BIIB021

    BIIB021は、Hsp90の新しい阻害剤で、 Ki と EC50 がそれぞれ 1.7 nM と 38 nMです。

  • NVP-BEP800

    NVP-BEP800は、新しい、完全に合成、口のHsp90β阻害剤で、 IC50 が 58 nMになる。

  • SNX-2112 (PF-04928473)

    SNX-2112 (PF-04928473)は、Hsp90家族Hsp90αとHsp90βのATPポケットと、選択的に結合します。 Ka がそれぞれ 30 nM と 30 nMです。

  • PF-04929113 (SNX-5422)

    PF-04929113(SNX-5422)は、41nMのKdによる強力で選択的なHsp90阻害剤で、そのうえ37nMのIC50で、Her-2退廃を妨げます。

  • KW-2478

    KW-2478は、強力で選択的なPDE10A阻害剤で、 IC50 が 0.37 nMです。

最近見られたアイテム

Tags: 17-AAG (Tanespimycin)を買う | 17-AAG (Tanespimycin)供給者 | 17-AAG (Tanespimycin)を購入する | 17-AAG (Tanespimycin)費用 | 17-AAG (Tanespimycin)生産者 | オーダー17-AAG (Tanespimycin) | 17-AAG (Tanespimycin)代理店
お問い合わせ